Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22166986 | 0.88 | CXCR4 (0.52) | CXCR4KDM4EALDH1A1GAAKDM5C | |
| SCHEMBL2817557 | 0.85 | CYP1A2 (0.55) | CYP1A2MAPTKDM4EALDH1A1GAA | |
| SCHEMBL26088149 | 0.84 | CXCR4 (0.41) | CYP1A2CXCR4MAPTKDM4EALDH1A1 | |
| SCHEMBL22166985 | 0.83 | CXCR4 (0.48) | CXCR4KDM4EKDM5CKDM4CBCHE | |
| SCHEMBL23790268 | 0.82 | CXCR4 (0.52) | CXCR4MAPTKDM4EALDH1A1GAA | |
| SCHEMBL19013529 | 0.82 | CXCR4 (0.57) | CXCR4KDM4EALDH1A1GAAKDM5C | |
| SCHEMBL26849946 | 0.82 | CXCR4 (0.57) | CXCR4KDM4EGAAKDM5CKDM4C | |
| SCHEMBL17708319 | 0.80 | CXCR4 (0.58) | CXCR4KDM4EGAAKDM5CKDM4C | |
| SCHEMBL16705677 | 0.79 | CXCR4 (0.61) | CXCR4KDM4EGAAKDM5CKDM4C | |
| SCHEMBL23780012 | 0.79 | CXCR4 (0.61) | CXCR4KDM4EGAAKDM5CKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976850-B1 | NOVEL LANTHANIDE LIGANDS AND COMPLEXES, AND USE THEREOF AS CONTRAST AGENTS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-20100247448-A1 | NOVEL LANTHANIDE LIGANDS AND COMPLEXES, AND USE THEREOF AS CONTRAST AGENTS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247448-A1 | NOVEL LANTHANIDE LIGANDS AND COMPLEXES, AND USE THEREOF AS CONTRAST AGENTS | SLC39A11, LPO, ZYX | CYP1A2 1790/4885CXCR4 80/4885MAPT 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.